Furthermore, the mutations of ADAM family members were assessed in gliomas, and ADAMTS20, ADAMTSL1 (ADAMTS-like protein 1), and ADAMTSL9 mutation probability was as high as 3%; other ADAM family members also had a series of mutations that were mainly concentrated in amplification (Figure 1B). This evidence concerns the gene ADAMTS20 and central nervous system cancer.